- Home
- CELC vs RNST Comparison
CELC vs RNST Comparison
Compare CELC & RNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- RNST
- Stock Information
- Founded
- CELC 2011
- RNST 1904
- Country
- CELC United States
- RNST United States
- Employees
- CELC N/A
- RNST N/A
- Industry
- CELC Medical Specialities
- RNST Major Banks
- Sector
- CELC Health Care
- RNST Finance
- Exchange
- CELC Nasdaq
- RNST Nasdaq
- Market Cap
- CELC 3.1B
- RNST 3.7B
- IPO Year
- CELC 2017
- RNST N/A
- Fundamental
- Price
- CELC $74.11
- RNST $34.18
- Analyst Decision
- CELC Strong Buy
- RNST Strong Buy
- Analyst Count
- CELC 5
- RNST 6
- Target Price
- CELC $69.40
- RNST $43.17
- AVG Volume (30 Days)
- CELC 1.4M
- RNST 579.7K
- Earning Date
- CELC 11-12-2025
- RNST 10-28-2025
- Dividend Yield
- CELC N/A
- RNST 2.59%
- EPS Growth
- CELC N/A
- RNST N/A
- EPS
- CELC N/A
- RNST 1.84
- Revenue
- CELC N/A
- RNST $775,365,000.00
- Revenue This Year
- CELC N/A
- RNST $42.94
- Revenue Next Year
- CELC N/A
- RNST $12.57
- P/E Ratio
- CELC N/A
- RNST $18.53
- Revenue Growth
- CELC N/A
- RNST 13.05
- 52 Week Low
- CELC $7.58
- RNST $26.97
- 52 Week High
- CELC $83.00
- RNST $40.40
- Technical
- Relative Strength Index (RSI)
- CELC 64.02
- RNST 42.05
- Support Level
- CELC $71.06
- RNST $33.04
- Resistance Level
- CELC $79.97
- RNST $34.68
- Average True Range (ATR)
- CELC 5.13
- RNST 0.81
- MACD
- CELC 0.11
- RNST 0.05
- Stochastic Oscillator
- CELC 53.43
- RNST 43.02
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About RNST Renasant Corporation
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has three reportable segments: Community banks, Insurance, and Wealth management. With its Community banks segment, the company provides a range of financial services to individuals and small businesses. Its Insurance segment is an insurance agency providing commercial and personal insurance through third-party carriers. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.